Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02143414 · ClinicalTrials.gov registry record · Phase 2

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

A Phase 2 study of Acute Lymphoblastic Leukemia and Refractory Acute Lymphoblastic Leukemia, sponsored by National Cancer Institute (NCI).

Active
Registry status
Phase 2
Development phase
53
Enrollment target
20
Study locations

NCT02143414: Active Phase 2 study of Acute Lymphoblastic Leukemia and Refractory Acute Lymphoblastic Leukemia, sponsored by National Cancer Institute (NCI).

NCT02143414 is a Phase 2 study of Acute Lymphoblastic Leukemia and Refractory Acute Lymphoblastic Leukemia that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 53 participants, below the 382-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02143414, a Phase 2 study of Acute Lymphoblastic Leukemia and Refractory Acute Lymphoblastic Leukemia, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
53 participants
Enrollment target
20
Study locations

Study Summary

This phase II trial studies the side effects and how well blinatumomab and combination chemotherapy or dasatinib, prednisone, and blinatumomab work in treating older patients with acute lymphoblastic leukemia. Immunotherapy with monoclonal antibodies, such as blinatumomab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as prednisone, vincristine sulfate, methotrexate, and mercaptopurine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving blinatumomab with combination chemotherapy or dasatinib and prednisone may kill more cancer cells.

Primary Outcome

To evaluate the 3-year overall survival rate in elderly participants with newly diagnosed Ph-negative ALL treated with blinatumomab followed by POMP maintenance. Overall

Conditions Studied

Acute Lymphoblastic Leukemia Refractory Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Recurrent Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Biopsy Procedure
  • BIOLOGICAL Blinatumomab
  • PROCEDURE Bone Marrow Aspiration and Biopsy

Study Locations (20)

California

  • City of Hope Comprehensive Cancer Center - Duarte
  • UC San Diego Moores Cancer Center - La Jolla
  • Loma Linda University Medical Center - Loma Linda
  • Los Angeles General Medical Center - Los Angeles
  • USC / Norris Comprehensive Cancer Center - Los Angeles
  • USC Norris Oncology/Hematology-Newport Beach - Newport Beach
  • UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
  • Keck Medical Center of USC Pasadena - Pasadena

Illinois

  • Rush-Copley Medical Center - Aurora
  • OSF Saint Joseph Medical Center - Bloomington
  • Illinois CancerCare-Bloomington - Bloomington

Arizona

  • Banner University Medical Center - Tucson - Tucson
  • University of Arizona Cancer Center-North Campus - Tucson

Connecticut

  • Smilow Cancer Center/Yale-New Haven Hospital - New Haven
  • Yale University - New Haven

Georgia

  • Northside Hospital - Atlanta
  • Augusta University Medical Center - Augusta

Alabama

  • University of Alabama at Birmingham Cancer Center - Birmingham

Arkansas

  • John L McClellan Memorial Veterans Hospital - Little Rock

Florida

  • Orlando Health Cancer Institute - Orlando

Trial Details

FieldValue
Enrollment Target 53 participants
Start Date 2015-06-30
Est. Completion 2027-01-26
Phase Phase 2
National Cancer Institute (NCI)

3,257 total trials

What the registry record for NCT02143414 still lists

NCT02143414 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 382-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (86% lower).

The record links to 5 conditions, with Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT02143414 names 20 study sites across 8 states, led by California, Illinois, Arizona.

Frequently Asked Questions

What is clinical trial NCT02143414 about?

NCT02143414 is a clinical study titled "Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia". This phase II trial studies the side effects and how well blinatumomab and combination chemotherapy or dasatinib, prednisone, and blinatumomab work in treating older patients with acute lymphoblastic leukemia. Immunotherapy with monoclonal antibodies, such as blinatumomab, may help the body's immune...

What is the current status of trial NCT02143414?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2015-06-30. Estimated completion is 2027-01-26.

What conditions does trial NCT02143414 study?

This clinical trial studies the following conditions: Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1.

What interventions are being tested in trial NCT02143414?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy Procedure (PROCEDURE), Blinatumomab (BIOLOGICAL), Bone Marrow Aspiration and Biopsy (PROCEDURE).

Who is sponsoring clinical trial NCT02143414?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02143414 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Lymphoblastic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02143414's enrollment target sits among peer trials

53 69th of 131 higher than 63 of 131 other Acute Lymphoblastic Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Lymphoblastic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04177004 · 53 participants · Phase 1

    Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

  • NCT04199741 · 53 participants · Phase 1

    PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

  • NCT04835129 · 53 participants · Phase 2

    Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

  • NCT04913805 · 53 participants · Phase 2

    Matching Perfusion and Metabolic Activity in HFpEF

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02143414, the US trial registry maintained by the National Library of Medicine. NCT02143414 (small enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.